Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 16, 2022
Daily News
December 16, 2022
- Ministers Agree on “4.375%” Product Coverage Line for 2023 “Off-Year” Drug Price Revision
December 16, 2022
- PeptiDream, Takeda Expected to Select 1st Oligo-PDC Candidate in 2023
December 16, 2022
- Eisai, Washington University to Team Up on Neurodegenerative Disease Therapies
December 16, 2022
- Twymeeg Most Promoted Drug in GP Market for 4 Months Straight in October: Intage
December 16, 2022
- Sunovion Offloads Lunesta to Woodward Pharma
December 16, 2022
- Off-Year Re-Pricing Expected to Cover 70% of Listed Products; Special Steps for Unprofitable Drugs, Patented Meds
December 16, 2022
- Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…